FDA labels recall of blood bypass pump systems by LivaNova as most serious

Sep. 30, 2022 11:49 AM ETLivaNova PLC (LIVN)By: Anuron Mitra, SA News Editor

Man hold the flash card with handwriting word FDA recall on wood background

bankrx/iStock via Getty Images

  • The U.S. Food and Drug Administration (FDA) on Friday classified the recall of several hundred blood bypass pump systems by LivaNova (NASDAQ:LIVN) as the most serious type.
  • LivaNova (LIVN) in July recalled 484 LifeSPARC Systems in the U.S. distributed between Dec. 2019 to present.
  • The LifeSPARC system is used to pump blood through a circuit outside of the body for periods lasting less than 6 hours in cardiopulmonary or circulatory bypass procedures.
  • LIVN initiated the recall due to a possible software malfunction in a controller which is part of the system. The malfunction could lead to the device entering critical failure mode.
  • The FDA on Friday classified the recall as a Class I recall, the most serious type as per its rules.
  • LIVN said there have been 66 complaints regarding the issue, while the FDA has received reports of two injuries and no deaths.
  • LivaNova (LIVN) stock +8.4% to $52.45 amid modest gains in broader U.S. markets.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.